2nd Quarter - Termination — PARDES BIOSCIENCES, INC. for PARDES BIOSCIENCES, INC. (2023)

Firm

PARDES BIOSCIENCES, INC.

Client

PARDES BIOSCIENCES, INC.

Income

—

Expenses

$120,000

Expense method

A: Lobbying Disclosure Act definitions

Terminated

Apr 12, 2023

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Funding for oral antivirals for covid.

Lobbyist	Covered position, as disclosed
JOHN MARTIN	Principal Associate Commissioner, FDA Legislative Affairs, Sen. Tom Cotton

Contacted: SENATE; Office of Science & Technology Policy (OSTP); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Pharmacy PHA

Physician prescribing of covid antivirals

Lobbyist	Covered position, as disclosed
JOHN MARTIN	Principal Associate Commissioner, FDA Legislative Affairs, Sen. Tom Cotton

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE; Office of Science & Technology Policy (OSTP)

Medicare/Medicaid MMM

Medicare coverage of oral antivirals

Lobbyist	Covered position, as disclosed
JOHN MARTIN	Principal Associate Commissioner, FDA Legislative Affairs, Sen. Tom Cotton

Contacted: HOUSE OF REPRESENTATIVES; Office of Science & Technology Policy (OSTP); SENATE

Medical/Disease Research/Clinical Labs MED

NIH funding for clinical trials

Lobbyist	Covered position, as disclosed
JOHN MARTIN	Principal Associate Commissioner, FDA Legislative Affairs, Sen. Tom Cotton

Contacted: Natl Institutes of Health (NIH)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.